At 22:38 on December 29th, Beijing time, Metacrine Inc (MTCR.us) shares changed, and the share price rose rapidly by 5.67%. As of press time, the stock was trading at US $0.440 per share, with a turnover of 816 sharesTurnover rate0.005%, amplitude 0.19%.
Recent financial report data show that the Unit has achievedbusiness income0.00 US dollarsNet profit-$5.52 millionEarnings per share-$0.13Gross profit0.00 US dollars, with a price-earnings ratio of-0.41 times.
In terms of agency rating, 100% of the brokerages gave holding advice and no brokerage gave buy and sell advice among all the 1 rating agencies.
The biotech industry in which Metacrine Inc shares are located rose 0.42 per cent as a whole. Among its related stocks, Baudax Bio Inc, Quoin Pharmaceuticals Ltd and Transcode Therapeutics Inc rose significantly, while Baudax Bio Inc, Transcode Therapeutics Inc and Quoin Pharmaceuticals Ltd were more active, with turnover rates of 2181.15%, 36.16% and 6.85%, respectively. The related stocks with larger amplitudes were Marizyme Incorporated, Baudax Bio Inc, and Xenetic Biosciences Inc C/Wts 19shock 07Compact 2024 (To Pur Com), with amplitudes of 35.33%, 30.00% and 27.30%, respectively.
About Metacrine Inc: Metacrine Inc is a clinical biopharmaceutical company dedicated to the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. The project targets the Fanisio X receptor, or FXR, which is central to the regulation of liver and gastrointestinal diseases. Its FXR candidates include MET409 and MET642.
At the news level, as of 22:38, the proportion of positive public opinion news on Metacrine Inc shares was 100%.
(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )